Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | CDC25B | P30305 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16049088 | 1.00 | TSHR (0.54) | TSHRBLMPTPN1LMNAL3MBTL1 | |
| SCHEMBL3577630 | 1.00 | TSHR (0.54) | TSHRBLMPTPN1LMNAL3MBTL1 | |
| SCHEMBL11718137 | 0.94 | LMNA (0.54) | TSHRBLMPTPN1LMNAL3MBTL1 | |
| SCHEMBL23673152 | 0.92 | LMNA (0.52) | TSHRBLMPTPN1LMNAL3MBTL1 | |
| SCHEMBL23673108 | 0.92 | LMNA (0.52) | TSHRBLMPTPN1LMNAL3MBTL1 | |
| SCHEMBL11949388 | 0.92 | BLM (0.52) | TSHRBLMPTPN1LMNAL3MBTL1 | |
| SCHEMBL11949385 | 0.92 | BLM (0.52) | TSHRBLMPTPN1LMNAL3MBTL1 | |
| SCHEMBL11949396 | 0.92 | BLM (0.52) | TSHRBLMPTPN1LMNAL3MBTL1 | |
| SCHEMBL130826 | 0.92 | TSHR (0.64) | TSHRPTPN1LMNAL3MBTL1ALDH1A1 | |
| SCHEMBL23673107 | 0.90 | L3MBTL1 (0.53) | TSHRBLMPTPN1LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120053668-A | Topical preparation containing lipid formed by non-lamellar liquid crystal | 法纳克斯株式会社 | 2025-05-30 | — | — | CN | disclosed |
| US-12296014-B2 | External preparation comprising non-lamellar liquid crystal-forming lipid | FARNEX INCORPORATED (JP) | 2025-05-13 | — | — | US | disclosed |
| CN-112770778-B | Topical preparation containing lipid formed by non-lamellar liquid crystal | 法纳克斯株式会社 | 2025-03-04 | — | — | CN | disclosed |
| CN-117794519-A | Non-lamellar liquid crystal forming composition and use thereof | 法纳克斯株式会社 | 2024-03-29 | — | — | CN | disclosed |
| US-20230105725-A1 | HIGHLY SAFE NON-LAMELLAR LIQUID CRYSTAL FORMING COMPOSITION | FARNEX INCORPORATED (JP) | 2023-04-06 | — | — | US | disclosed |
| CN-115461084-A | Non-lamellar liquid crystal forming composition with high safety | 法纳克斯株式会社 | 2022-12-09 | — | — | CN | disclosed |
| EP-4098281-A1 | HIGHLY SAFE NON-LAMELLAR LIQUID CRYSTAL FORMING COMPOSITION | Farnex Incorporated (JP) | 2022-12-07 | — | — | EP | disclosed |
| US-20210330794-A1 | EXTERNAL PREPARATION COMPRISING NON-LAMELLAR LIQUID CRYSTAL-FORMING LIPID | FARNEX INCORPORATED (JP) | 2021-10-28 | — | — | US | disclosed |
| EP-3848052-A1 | EXTERNAL PREPARATION COMPRISING NON-LAMELLAR LIQUID CRYSTAL-FORMING LIPID | Farnex Incorporated (JP) | 2021-07-14 | — | — | EP | disclosed |
| CN-112770778-A | External preparation containing non-lamellar liquid crystal forming lipid | 法纳克斯株式会社 | 2021-05-07 | — | — | CN | disclosed |
| US-20160067208-A1 | ADHESION PREVENTING AGENT | FARNEX INCORPORATED (JP) | 2016-03-10 | — | — | US | disclosed |
| EP-2992910-A1 | ADHESION PREVENTING AGENT | Farnex Incorporated (JP) | 2016-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210330794-A1 | EXTERNAL PREPARATION COMPRISING NON-LAMELLAR LIQUID CRYSTAL-FORMING LIPID | LIPA, LIPC, CETP | TSHR 2888/4885BLM 1043/4885PTPN1 931/4885 |
| US-12296014-B2 | External preparation comprising non-lamellar liquid crystal-forming lipid | LIPA, LIPC, CETP | TSHR 2888/4885BLM 1043/4885PTPN1 931/4885 |
| US-20160067208-A1 | ADHESION PREVENTING AGENT | EPCAM, ICAM1, VCAM1 | TSHR 4554/4885BLM 976/4885PTPN1 1953/4885 |
| US-20230105725-A1 | HIGHLY SAFE NON-LAMELLAR LIQUID CRYSTAL FORMING COMPOSITION | LIPA, PHOSPHO1, PLA2G12A | TSHR 3779/4885BLM 228/4885PTPN1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.